Sellas' GPS Trial Hits 80th Event; SLS Shares Drop 18%
Sellas Life Sciences reported the 80th event in the Phase 3 Regal trial of GPS, which triggers the final analysis. Shares fell 18%, according to Stocktwits.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Stocktwits reports that Sellas Life Sciences (SLS) drew attention on Wednesday after the company reached a key point in its pivotal leukemia study of galinpepimut-S (GPS). The Phase 3 Regal trial recorded its 80th event, meaning a death, and that triggered the final analysis.
Next, the company will lock the database, unblind the study data and run statistical analysis of the primary endpoint. Sellas plans to announce preliminary topline results later this quarter, but gave no specific date. Meanwhile the shares dropped 18%, their biggest single-day loss since March 2024.
The 126-patient study enrolled people with acute myeloid leukemia who went into remission after a relapse. GPS is being compared with the best available treatment on overall survival.
why it matters
For traders the main issue is uncertainty: the data stay sealed until unblinding, and no date has been set. Short interest in SLS stands at 27.3% per Koyfin, and the stock is up more than 130% this year against about 35% for XBI, so expectations are already high.
market impact
SLS shares: uncertainty before trial data adds volatility and pressures the stock
tags
instruments
sources
- Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18% — Stocktwits, 28 October 2026 at 16:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗